Business
Candid Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14th
SAN DIEGO, January 06, 2026--Candid Therapeutics, Inc. ("Candid"), a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs), today announced that Dr. Ken Song, Chairman, President and Chief Executive Officer, will present at the J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 7:30 a.m. PT, at The Westin St. Francis Hotel in San Francisco.
About this update from Jp Morgan Chase & Co.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":245,"url":"https://media.zenfs.com/en/business-wire.com/7b5d2e95debb947b3d8caaea1bf14b31"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ENP1PTmvMaP23BMZQ.9xug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ5MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/7b5d2e95debb947b3d8caaea1bf14b31","width":480,"height":245}},"lazy":false},{"type":"text","content":"SAN DIEGO, January 06, 2026--(BUSINESS WIRE)--Candid Therapeutics, Inc. ("Candid"), a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs), today announced that Dr. Ken Song, Chairman, President and Chief Executive Officer, will present at the J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 7:30 a.m. PT, at The Westin St. Francis Hotel in San Francisco.","length":472,"tagName":"p"},{"type":"text","content":"Dr. Song’s presentation will highlight Candid’s continued clinical momentum, including progress across its T-cell engager portfolio.","length":132,"tagName":"p"},{"type":"text","content":"About Candid Therapeutics","length":25,"tagName":"p"},{"type":"text","content":"Candid Therapeutics is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune and inflammatory diseases through novel T-cell engager (TCE) platforms. Candid is advancing two lead B-cell depleting TCEs, with a goal to broadly explore the potential of TCEs across multiple autoimmune diseases by targeting different B-cell protein targets, as well as evaluating different depths of B-cell depletion. Established in 2024 and headquartered in San Diego, CA, Candid is led by a team of entrepreneurial executives who have a track record of advancing programs into and through development and is supported by a distinguished syndicate of premier life science investors.","length":699,"tagName":"p"},{"type":"text","content":"View source version on businesswire.com: https://www.businesswire.com/news/home/20260106303536/en/","length":98,"tagName":"p"},{"type":"text","content":"Contacts","length":8,"tagName":"p"},{"type":"text","content":"Arvind [email protected]","length":29,"tagName":"p"}]